Nature Communications (Apr 2021)
ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
- Youqian Wu,
- Chao Zhang,
- Xiaolan Liu,
- Zhengfu He,
- Bing Shan,
- Qingxin Zeng,
- Qingwei Zhao,
- Huaying Zhu,
- Hongwei Liao,
- Xufeng Cen,
- Xiaoyan Xu,
- Mengmeng Zhang,
- Tingjun Hou,
- Zhe Wang,
- Huanhuan Yan,
- Shuying Yang,
- Yaqin Sun,
- Yanying Chen,
- Ronghai Wu,
- Tingxue Xie,
- Wei Chen,
- Ayaz Najafov,
- Songmin Ying,
- Hongguang Xia
Affiliations
- Youqian Wu
- Department of Biochemistry and Research Center of Clinical Pharmacy of The First Affiliated Hospital, Zhejiang University School of Medicine
- Chao Zhang
- International Institutes of Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Xiaolan Liu
- Department of Biochemistry and Research Center of Clinical Pharmacy of The First Affiliated Hospital, Zhejiang University School of Medicine
- Zhengfu He
- Department of Thoracic Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- Bing Shan
- Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
- Qingxin Zeng
- Department of Thoracic Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
- Qingwei Zhao
- Department of Biochemistry and Research Center of Clinical Pharmacy of The First Affiliated Hospital, Zhejiang University School of Medicine
- Huaying Zhu
- Department of Cell Biology and Department of Cardiology of the Second Affiliated Hospital, Zhejiang University School of Medicine
- Hongwei Liao
- Key Laboratory Respiratory Disease of Zhejiang Province, Department of Pharmacology and Department of Respiratory and Critical Care Medicine of the Second Affiliated Hospital, Zhejiang University School of Medicine
- Xufeng Cen
- Department of Biochemistry and Research Center of Clinical Pharmacy of The First Affiliated Hospital, Zhejiang University School of Medicine
- Xiaoyan Xu
- Department of Biochemistry and Research Center of Clinical Pharmacy of The First Affiliated Hospital, Zhejiang University School of Medicine
- Mengmeng Zhang
- Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences
- Tingjun Hou
- Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University
- Zhe Wang
- Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University
- Huanhuan Yan
- Department of Biochemistry and Research Center of Clinical Pharmacy of The First Affiliated Hospital, Zhejiang University School of Medicine
- Shuying Yang
- Department of Biochemistry and Research Center of Clinical Pharmacy of The First Affiliated Hospital, Zhejiang University School of Medicine
- Yaqin Sun
- Department of Biochemistry and Research Center of Clinical Pharmacy of The First Affiliated Hospital, Zhejiang University School of Medicine
- Yanying Chen
- Department of Biochemistry and Research Center of Clinical Pharmacy of The First Affiliated Hospital, Zhejiang University School of Medicine
- Ronghai Wu
- Department of Biochemistry and Research Center of Clinical Pharmacy of The First Affiliated Hospital, Zhejiang University School of Medicine
- Tingxue Xie
- Department of Biochemistry and Research Center of Clinical Pharmacy of The First Affiliated Hospital, Zhejiang University School of Medicine
- Wei Chen
- Department of Cell Biology and Department of Cardiology of the Second Affiliated Hospital, Zhejiang University School of Medicine
- Ayaz Najafov
- Department of Cell Biology, Harvard Medical School
- Songmin Ying
- International Institutes of Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Hongguang Xia
- Department of Biochemistry and Research Center of Clinical Pharmacy of The First Affiliated Hospital, Zhejiang University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-021-22467-8
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
The regulation of PD-L1 via proteasomal degradation is unclear. Here, the authors show that EGFR inhibition activates GSK3 α to promote PD-L1 phosphorylation, which leads to PD-L1 ubiquitination and proteasome mediated degradation by ARIH1 E3 ligase.
